Abstract
Background: As genetic information moves from basic research laboratories in to the clinical testing environment, there is a critical need for reliable reference materials for the quality assurance of genetic tests. A panel of 12 plasmid clones containing wild-type or point mutations within exons 5–9 have been developed as reference materials for the detection of TP53 mutations.
Aim: The goal of this study was to validate the reference materials in providing quality assurance for the detection of TP53 mutations in clinical specimens.
Methods: We studied 33 gynecological samples, 11 apparently normal samples and 22 malignant tumors of various origins. Mutations were identified using single-strand conformational polymorphism analysis with both slab gel and capillary electrophoresis. All DNA samples were amplified with fluorescently labeled PCR primers specific for exons 5–9 for mutation detection.
Results: Of the 33 patient samples tested, mutations and polymorphisms were found in six specimens in three of the five exons scanned; no mutations were found in exons 7 or 9. Both a mutation and polymorphism were found in non-malignant specimens from the control group. The mutations were confirmed by DNA sequence analysis of the regions scanned.
Conclusions: Mutations and polymorphisms were detected in the clinical samples. All of the mutations were silent except for one non-conservative mutation in exon 5, codon 181. This study demonstrates the usefulness of the National Institute of Standards and Technology (NIST) TP53 reference panel in TP53 mutation detection in clinical tissue specimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hollstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancer. Science 1991; 253: 49–53
Vogelstein B, Kinzer K. p53 function and dysfunction. Cell 1992; 70: 523–6
Somlo G, Simpson JF, Frankel P, et al. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer 2002; 87: 281–8
Liu MC, Gelmann EP. p53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002; 29: 246–57
Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erb B-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505–12
Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26
O’Connell CD, Tully LA, Devaney JM, et al. Renewable standard reference material for the detection of TP53 mutations. Mol Diagn 2003; 7: 85–97
Orita M, Iwahana H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A 1989; 86: 2766–70
Eng C, Brody LC, Wagner TMU, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001; 38: 824–33
Kristensen VN, Kelefiotis D, Kristensen T, et al. High-throughput methods for detection of genetic variation. Biotechniques 2001; 30: 318–32
Ellis LA, Taylor CF, Taylor GR. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat 2000; 15: 556–64
Cotton RGH. Mutation detection 2001: novel technologies, developments and applications for analysis of the human genome. Hum Mutat 2002; 19: 313–4
Liu Q, Feng J, Buzin C, et al. Detection of virtually all mutations-SSCP (DOVAMS): a rapid method for mutation scanning with virtually 100% sensitivity. Biotechniques 1999; 26: 932–42
Serov SF, Soully RF. Histological typing of ovarian tumors. In: International Histological classification of tumors. Geneva: World Health Organization, 1973
O’Connell CD, Tian J, Juhaz A, et al. Development of standard reference materials for diagnosis of p53 mutations: analysis by slab-gel single-stand conformation polymorphism. Electrophoresis 1998; 19: 164–71
O’Connell CD, Atha DH, Oldenburg MC, et al. Detection of p53 gene mutations: analysis by single strand conformation polymorphism and cleavase fragment length polymorphism. Electrophoresis 1999; 20: 1211–23
Atha DH, Wenz HM, Morehead H, et al. Detection of p53 point mutations by single strand conformation polymorphism: analysis by capillary electrophoresis. Electrophoresis 1998; 19: 172–9
Wenz HM, Ramachandra S, O’Connell CD, et al. Identification of known p53 point mutations by capillary electrophoresis using unique mobility profiles in a blinded study. Mut Res Genom 1998; 382: 121–32
WHO IARC TP53 mutation database: polymorphisms in the TP53 gene [online]. International Agency for Research on Cancer. Updated 2003 Jun 24. Available from URL: http://www.iarc.fr/P53/Polymorphism.html [Accessed 2004 Aug 23]
Frequencies of TP53 mutations. WHO IARC TP53 Mutation Database [online]. R8, International Agency for Research on Cancer. Updated 2003 Jun 24. Available from URL: http://www.iarc.fr/p53/ [Accessed 2004 Sep 2]
Acknowledgements
Certain commercial equipment, instruments, materials, or companies are identified in this paper to specify adequately the experimental procedure. Such identification does not imply recommendation nor endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are the best available for the purpose.
Dr Sunar-Reeder and Dr Atha contributed equally to the study.
This study was funded using funds appropriated by the Congress of the United States to the National Institute of Standards and Technology, an agency of the United States government. The authors were federal employees at the time the article was written and are subject to the conflict of interest laws governing federal employees.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sunar-Reeder, B., Atha, D.H., Aydemir, S. et al. Use of TP53 reference materials to validate mutations in clinical tissue specimens by single-strand conformational polymorphism analysis. CNS Drugs 8, 123–130 (2004). https://doi.org/10.1007/BF03260055
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03260055